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Figure 3.  There is a statistical difference between the control group and all other 
groups which   have the star symbol above them.  These differences are statistically 
relevant with a P value equal to or less than 0.006.  The decrease in cell viability 
explains the decrease in wound healing seen in the WI38 wound healing assay. 
Abstract 
Benzathonium chloride (BTC) is a quaternary ammonium compound 
(QAC) that is used as an antibacterial in several applications1. BTC can 
be complexed with laponite clay (Bioclay) particles, making it capable of 
being applied and retained topically2. Once complexed, BTC cannot be 
easily leached out of the clay by diffusion due to strong interactions with 
the clay surface. Bioclay has a wide range of potential applications for 
imparting antimicrobial activity in medical, industrial, and household 
applications. Bioclay has been previously shown to be effective against 
methicillin resistant Staphylococcus aureus (MRSA), and has been 
developed in cream form for topical application as an antibacterial 
cream1. This study investigates the hypothesis that BTC, when 
incorporated into a pharmaceutical grade colloid, can enhance the 
process of wound healing. This is done using an in vitro wound healing 
model utilizing a variety of cell lines. WI38 cells are normal diploid human 
fibroblasts. TM12 and TM12T are immortalized mammary epithelial cell 
lines;TM12T is a derivative of TM12 and has undergone epithelial to 
mesenchymal transition. The first study utilized the TM12 cells which 
were epithelial in appearance and when confluent looked cuboidal and 
tightly joined. The cells tended to maintain cell to cell connections after 
being scraped in order to induce the wound and as an attempt to prevent 
this flap of cells from falling back into the wound the well was washed 
with PBS before the different medias were added.  In this study an 
induced “wound” on a confluent well is treated with media or media 
treated with either BTC or Bioclay. The wound width was measured after 
24 hours to compare the width of the wounds between the control and 
treatment groups.  A viability assay was run in parallel, to control for any 
effects of BTC compounds on total viable cell number. No effect was 
seen on wound healing at any of the concentrations tested, in either 
fibroblast, epithelial or EMT epithelial cell lines. Lack of effect was not 
due to loss of viability. Although no effect was seen of BTC compounds 
on these purified cell lines, in vivo wound healing may still be affected, 
due to the coordinated participation of several cell types, including 
granulocytes, macrophages, fibroblasts, and epithelial cells.  
Methods 
Results 
Discussion 
Wound healing assays Cells were plated in 24 well plates at 5X104 
cells/well and grown to confluence. The confluent layer of cells in triplicate 
wells was then scratched from the top of the well down using a 
micropipette tip. Wells were rinsed with sterile PBS to remove detached 
cells. Cells were then fed with media containing 0, 1.25, 2.5, or 5 µg/ml 
BTC or BTC-clay. These concentrations were selected to be below 
concentrations previously used in a cream formulation (50 µg/ml), and 
based on literature that assessed the toxicity of BTC4. At 24 hours, 
images were taken using a phase contrast inverted microscope. Wound 
diameter was measured at two time points (0 and 24 hours) to assess % 
wound closure at 24h using the formula: 
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MTT Assay After photography of the wells, 200 µl of 5 mg/ml MTT was 
added to each well. After 4 hours, cells were photographed to show 
viability of cells in the culture. A colorimetric assay was then performed by 
harvesting cells quantitatively into isopropanol, and measuring the optical 
density of cells from each well at 595 nm.  
Statistical Analysis  All data Analysis was done using Sigma Plot 11.0.  
All of the groups were compared using one way ANOVAs with a 
significance level of 0.05.  The bars in the graphs are standard error. 
• There was no enhancement of wound healing responses in either 
WI38,TM12 or TM12T cells by BTC or Bioclay.   
• There was no difference in wound healing between the BTC and 
Bioclay groups for any of the cell lines used. 
• The TM12 cell line was more sensitive to the BTC and Bioclay than 
the TM12T cell line.   
• WI-38 fibroblast viability was more sensitive to Bioclay than BTC 
alone as seen in the viability assay. 
• At higher concentrations of BTC there was a slight loss of cell 
viability in TM12 cells, but TM12T cells were less sensitive to BTC 
which might be contributed to the cell’s more tumorigenic 
properties.  
• The use of the TM12 and TM12T cells as an in vitro wound healing 
model demonstrated that BTC and Bioclay do not inhibit wound 
healing in concentrations as high as 5.0 μg/ml.  There was also 
minimal effects on cytotoxicity at these levels. 
• There are limitations to using a single cell in vitro model , such as the 
lack of cell to cell interactions between the many different cells in the 
wound bed, that will require the use of an in vivo model to observe. 
• The lack of an in vitro effect may not predict an in vivo effect. The 
in vitro studies do not mimic the in vivo environment in which 
multiple cell types (granulocytes, macrophages, fibroblasts, and 
epithelial cells) participate. An in vivo wound healing assays will be 
useful to test the effects of Bioclay on myriad cell types in the 
physiological wound bed.   
• This study suggests that the mechanism of any BTC induced 
increase in wound healing in vivo is not likely a result of a direct effect 
on cellular proliferation, but rather, through its antimicrobial effect of 
decreasing microbial proliferation within the wound bed. 
Introduction 
Wound beds are complex environments in which dead tissue, exudate, 
and the bacterial bioburden interact in a complicated manner among 
themselves as well as the host.  In these situations, bacteria tend to 
organize into biofilms, reducing their susceptibility to elimination as well as 
impairing healing3.  The cleaning of the wound is one of the basics of 
standard care and help the healing of a chronic wound.  Published 
literature shows that cleaning improves the wound environment and 
accelerates healing,  In previous studies, BTC has proven to be affective 
against a number of bacteria including (but not limited to) E. coli, H. 
influenzae, S. typhi, S. aureus, and S pneumoniae4.  Anecdotal evidence 
from topical use of Bioclay has indicated that BTC complexed with 
laponite can have a positive effect on wound healing.  This is a fiirst 
attempt to understand the mechanism(s) by which this can occur.   
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Figure 1.  TM12 cells showing the progression of wound healing in control cultures at 
0 (A) and 24 hours (B).  The bars indicate measured distances used in calculating the 
percentage of the wound that has healed. 
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Figure 2.  WI38 wound healing assay results after 24 hours.  Although there is a 
decrease in wound healing seen in the graph, there is no  statistical decrease in 
wound healing.  There  was 42.1% wound healing observed in the control group. 
TM12 Wound Healing Assay
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Figure 4.  After 24 hours of incubation, the TM12 control group averaged 78.4% 
wound closure.  The wound closure of the control group was not statistically different 
from any of the BTC or Bioclay variable groups (P=0.863). 
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Figure 5. The TM12 MTT assay shows a slight decrease in cell viability as the 
concentration of either BTC or Bioclay increases however, there is no statistical (P 
< 0.05) difference between any of the groups with the control.  There was a 
difference between the  1.25 μg/ml BTC group and the 5.0 μg/ml Bioclay group (P 
= 0.029). 
Figure 6. After 24 hours of incubation, the TM12T control group averaged 88.0% 
wound closure.  The wound closure of the control group was not statistically different 
from any of the BTC or Bioclay variable groups (P=0.780).  
TM12T Wound Healing Assay
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(Width at time zero) - (Width at 24h)) / (Width at time zero) X 100.   A total 
of 3 plates were used in the wound healing assays of the TM12 and 
TM12T cells while there was only one plate used in the WI38 study 
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Figure 4. The TM12T MTT assay differs from the TM12 MTT assay in the fact that 
there is no decrease in cell viability (with a P < 0.05) except for the 5.0 μg/ml Bioclay 
group.  The 5.0 μg/ml Bioclay group was different from all the other groups with a P 
value of at most 0.006.  All of the other groups are statistically similar. 
